LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Presbyopia, the age-related loss of near vision, could soon be treated successfully
GV20 received an upfront payment and is eligible for additional milestone payments
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Diversifying its portfolio to include late-phase antiviral agent
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Subscribe To Our Newsletter & Stay Updated